Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5-billion expansion of manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results